Spiral blood flow improves success rate for vascular bypass surgery

21 November 2014

Dundee company Vascular Flow Technologies has presented data that shows a 30% increase in one-year success for patients who received the company's Spiral Flow graft for infrainguinal vascular bypass surgery compared to those who received a standard PTFE graft.

The data was presented at the 41st Annual VEITH Symposium on Vascular and Endovascular Issues in New York

The study was led by Mr Nick Shaper FRCS, Consultant Vascular Surgeon at Bradford Royal Infirmary, UK. Mr Shaper said: “All patients demonstrated post-operative spiral laminar flow at the distal anastomosis, and there was a substantial and highly encouraging improvement in one year patency rates in this group of patients.”

Studies have shown that the company's Spiral Laminar Flow (SLF) technology replicates natural blood flow by generating a spiral laminar flow within the graft, reducing turbulence at the point where the blood flows into the blood vessel, which limits changes to the blood vessel wall that may be precursors to thrombosis. These findings add to the growing body of evidence demonstrating improved clinical outcomes for patients who receive a Spiral Flow Graft.

At the Symposium, Professor Richard Neville, Chief of the Division of Vascular Surgery, George Washington University Hospital presented an update on the newly opened US registry for Spiral Flow arteriovenous (AV) grafts in haemodialysis access. The Spiral Flow AV Access Graft Clinical Registry will collect the primary, primary assisted and secondary patency rates of the Spiral Flow AV Access Graft in patients with end stage renal disease (ESRD) as well as recording complication rates.

The Registry will provide data to its physician users detailing their patients’ graft performance data compared to national performance. The registry will hold demographic, operative and postoperative graft performance data, and results. Findings will be presented at local, regional and national vascular conferences in the months ahead.

Bill Allan, CEO of Vascular Flow Technologies commented: “Clinical experience with Spiral Flow Grafts is continuing to grow, and the newly opened US registry will provide a further bank of data for evaluation of long-term patency and complication rates. We are encouraging haemodialysis physicians to view the portal and to seek Institutional Review Board (IRB) approval to start entering patient data.”

The Vascular Flow Clinical Registry portal can be accessed at www.vascular-flow-clinical-registry.com

Source: Vascular Flow Technologies


To top